News

The partnership establishes a major dystonia research prize to expand public awareness, acknowledge key scientific discoveries and incentivize the work of dedicated researchers in dystonia, an under-funded movement

The company will be developing an advanced, automated prototype system for human tissue immuno-oncology profiling, which it will deploy at two leading medical institutions over the course of

MGB-BP-3 is the first antibacterial for over a decade with a novel mode of action from a truly novel class to be developed globally. Funding of £2.7m has

The deal will see Sanofi provide about $200m in equity investments, milestone payments and research and development services over the next four years. Sanofi has already paid MyoKardia

Tildrakizumab is a humanized, anti-IL-23p19 monoclonal antibody that binds specifically to IL-23p19 and is designed to selectively block the cytokine IL-23. It is currently being evaluated in Phase

SGX301 is a first-in-class, photodynamic therapy using safe visible light for activation and its active ingredient, synthetic hypericin, is a potent photosensitizer which is topically applied to skin

Trelagliptin succinate is a once-weekly dipeptidyl peptidase-IV (DPP-4) inhibitor that controls blood glucose levels by selectively and continually inhibiting DPP-4, which helps in increasing insulin secretion depending on

As part of this partnership, around 20 more new products will be added to the current portfolio, with first launches likely to happen in 2016. With specific focus

GsMTx-4 was originally identified in tarantula venom by researchers at the State University of New York and was found to inhibit mechanosensitive calcium channels. The agent is a